597 reports of this reaction
3.0% of all TOBRAMYCIN SOLUTION reports
#6 most reported adverse reaction
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS is the #6 most commonly reported adverse reaction for TOBRAMYCIN SOLUTION, manufactured by Amneal Pharmaceuticals LLC. There are 597 FDA adverse event reports linking TOBRAMYCIN SOLUTION to INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS. This represents approximately 3.0% of all 19,799 adverse event reports for this drug.
Patients taking TOBRAMYCIN SOLUTION who experience infective pulmonary exacerbation of cystic fibrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS is a less commonly reported adverse event for TOBRAMYCIN SOLUTION, but still significant enough to appear in the safety profile.
In addition to infective pulmonary exacerbation of cystic fibrosis, the following adverse reactions have been reported for TOBRAMYCIN SOLUTION:
The following drugs have also been linked to infective pulmonary exacerbation of cystic fibrosis in FDA adverse event reports:
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS has been reported as an adverse event in 597 FDA reports for TOBRAMYCIN SOLUTION. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS accounts for approximately 3.0% of all adverse event reports for TOBRAMYCIN SOLUTION, making it a notable side effect.
If you experience infective pulmonary exacerbation of cystic fibrosis while taking TOBRAMYCIN SOLUTION, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.